Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness
出版年份 2020 全文链接
标题
Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness
作者
关键词
-
出版物
PHARMACOECONOMICS
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-06-25
DOI
10.1007/s40273-020-00936-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis
- (2020) Han Yang et al. Drug Design Development and Therapy
- The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction
- (2020) Zanfina Ademi et al. European Journal of Preventive Cardiology
- Cost-Effectiveness of Alirocumab
- (2019) Dhruv S. Kazi et al. ANNALS OF INTERNAL MEDICINE
- Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States
- (2019) Thomas A. Gaziano et al. AMERICAN HEART JOURNAL
- The cost-effectiveness of omega-3 polyunsaturated fatty acids – The Australian healthcare perspective
- (2019) Lan Gao et al. European Journal of Internal Medicine
- Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand
- (2019) Khachen Kongpakwattana et al. PHARMACOECONOMICS
- Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort
- (2019) Alexander Dressel et al. VASCULAR PHARMACOLOGY
- Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease
- (2019) Gregg C. Fonarow et al. JAMA Cardiology
- Transparency in Health Economic Modeling: Options, Issues and Potential Solutions
- (2019) Eric Q. Wu et al. PHARMACOECONOMICS
- Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study
- (2019) John K Lin et al. Lancet Global Health
- Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review
- (2019) Samad Azari et al. HEART FAILURE REVIEWS
- Cost-Effectiveness of Statin Plus Eicosapentaenoic Acid Combination Therapy for Cardiovascular Disease Prevention in Japanese Patients With Hypercholesterolemia ― An Analysis Based on the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS) ―
- (2018) Satoshi Kodera et al. CIRCULATION JOURNAL
- Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan
- (2018) Satoshi Kodera et al. CIRCULATION JOURNAL
- Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial
- (2018) Ziyad S. Almalki et al. Heart Lung and Circulation
- The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective
- (2018) Radya Kumar et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Increased Cardiovascular Risk in Hypertriglyceridemic Patients with Statin-Controlled LDL Cholesterol
- (2018) Gregory A Nichols et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Hypertriglyceridemia and omega-3 fatty acids: Their often overlooked role in cardiovascular disease prevention
- (2018) M. Arca et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Are PCSK9 Inhibitors Cost Effective?
- (2018) Max J. Korman et al. PHARMACOECONOMICS
- The Importance of Model Structure in the Cost-Effectiveness Analysis of Primary Care Interventions for the Management of Hypertension
- (2018) Maria Cristina Peñaloza-Ramos et al. VALUE IN HEALTH
- Cost-effectiveness of interventions to control cardiovascular diseases and diabetes mellitus in South Asia: a systematic review
- (2018) Kavita Singh et al. BMJ Open
- Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2018) Gregory A Roth et al. LANCET
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- A review of economic evaluations for beneficial health outcomes of micronutrient and long-chain omega-3 fatty acid supplementation
- (2017) Michèle Jeanne Sadler INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION
- Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial
- (2017) Dhruv S. Kazi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves
- (2017) Ankur Pandya et al. MEDICAL DECISION MAKING
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Utilidad de un policomprimido cardiovascular en el tratamiento de pacientes en prevención secundaria en España: un estudio de coste-efectividad
- (2017) Vivencio Barrios et al. REVISTA ESPANOLA DE CARDIOLOGIA
- Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease
- (2017) Dong-Churl Suh et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States
- (2017) Glenn M. Davies et al. JOURNAL OF MEDICAL ECONOMICS
- Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context
- (2017) Peter P. Toth et al. JOURNAL OF MEDICAL ECONOMICS
- Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers
- (2017) Alejandro Arrieta et al. JAMA Cardiology
- Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
- (2017) Gregg C. Fonarow et al. JAMA Cardiology
- Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease
- (2016) Robert Klempfner et al.
- Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
- (2016) Shravanthi R. Gandra et al. CLINICAL CARDIOLOGY
- Effectiveness of fixed dose combination medication (‘polypills’) compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries
- (2016) Ruth Webster et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
- (2016) Dhruv S. Kazi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease
- (2016) Robert Klempfner et al. Circulation-Cardiovascular Quality and Outcomes
- Cost-effectiveness of adherence-enhancing interventions: a systematic review
- (2016) Tzahit Simon-Tuval et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK
- (2015) V. Becerra et al. BMJ Open
- The combined use of aspirin, a statin, and blood pressure–lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease
- (2013) Melvin Lafeber et al. AMERICAN HEART JOURNAL
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2013) David Moher ANNALS OF INTERNAL MEDICINE
- Effects of a Fixed-Dose Combination Strategy on Adherence and Risk Factors in Patients With or at High Risk of CVD
- (2013) Simon Thom JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
- (2013) D. Husereau et al. BMJ-British Medical Journal
- Comparative Cost-Effectiveness of Interventions to Improve Medication Adherence after Myocardial Infarction
- (2012) Kouta Ito et al. HEALTH SERVICES RESEARCH
- Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease
- (2012) Brian A. Ference et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting
- (2011) Martin R. Cowie et al. EUROPEAN JOURNAL OF HEART FAILURE
- Projected Cost-Effectiveness of Ezetimibe/Simvastatin Compared with Doubling the Statin Dose in the United Kingdom: Findings from the INFORCE Study
- (2010) John Reckless et al. VALUE IN HEALTH
- Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland
- (2009) Erkki J.O. Soini et al. CURRENT MEDICAL RESEARCH AND OPINION
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started